EMEA-002369-PIP01-18-M01

Key facts

Active substance
Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains (bb2121)
Therapeutic area
Oncology
Decision number
P/0387/2019
PIP number
EMEA-002369-PIP01-18-M01
Pharmaceutical form(s)
Dispersion for injection
Condition(s) / indication(s)
Treatment of mature B-cell neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
Celgene Europe B.V.

Tel. +41 327298500
E-mail: medinfo.emea@celgene.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating